ER, PR and PFS

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend progression-free survival (PFS) in certain patients in a Phase III trial.
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
ER+ and PR+ Breast Cancer: Key Statistics and Molecular Insights
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.
Verzenio Combo May Improve Survival in HR+/HER2– Advanced Breast Cancer
Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a manageable safety profile.
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug
Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming late-stage trial data for vepdegestrant, an experimental breast cancer therapy it co-develops with Pfizer (NYSE:PFE).
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
MedPage Today on MSN16d
Novel Drug Shrinks 73% of HER2-Mutant Lung Cancers
"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically unfavourable mutation," according to Wolfgang Brueckl, MD, of t ...
Medscape18d
EGFR/HER2 in Breast Cancer: A Biological Approach for Molecular Diagnosis and Therapy
EGF receptor (EGFR) and HER2 are two members of the ErbB/HER-family of tyrosine-kinase receptors that are frequently altered in breast cancer and several other malignancies, which inspired the ...
Monthly Prescribing Reference22d
Zongertinib Under Review for HER2-Mutant Advanced NSCLC
Zongertinib is an orally-administered, irreversible tyrosine kinase inhibitor that selectively blocks HER2 (ERBB2), while sparing wild-type epidermal growth factor receptor (EGFR), thereby ...
Pharmabiz2d
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial
Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...